Cortical inhibition in @entity191 : new insights from early, untreated XXXX .

@entity1 @entity1162 @entity191
Transcranial magnetic stimulation (TMS) has opened important perspectives on the pathophysiological bases and potential targets of treatment strategies for @entity191 ( @entity191 ). Studies have been mainly focusing on motor cortical inhibitory phenomena. However, differences in @entity1 and methods caused several discrepancies, particularly on the so-called @entity1162 ( @entity1162 ). We wanted to challenge such controversies by studying early, drug-na  ve @entity1 , and by reproducing the original method that detected a pathologic @entity1162 in @entity191 . We studied the motor potentials evoked in the first dorsal interosseous muscle on the more and the less @entity191 side of the body in 18 asymmetrical untreated @entity191 @entity1 in the early stages of their disease. We had 12 healthy controls. The TMS variables were the active motor threshold, the size of the motor-evoked potential, the cortical silent period and @entity1162 . Average active motor threshold was similar in @entity1 and controls, but its variability was significantly higher among @entity1 (P<0.05). There was a trend for the cortical silent period to be shorter on the more affected side of the @entity1 (P=0.1). @entity1 , especially on their more affected side, exhibited a late @entity1162 peak, which was absent among controls (P<0.05). This effect was independent of the silent period duration. However, @entity1 and controls having a short silent period also had a shorter @entity1162 (P<0.05). Changes in @entity1162 had a strong trend to correlate to the severity of the @entity191 signs (P=0.1). Thus, the present study definitely reinforced several previous TMS findings in @entity191 as a feature of the "pure" disease pathophysiology. The pathologic enhancement of late @entity1162 can act as a candidate physiological hallmark of @entity191 , to be tested in various diagnostic or therapeutic circumstances.
